康芝药业(300086) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥104,742,326.30, a decrease of 40.01% compared to ¥174,602,090.13 in the same period last year[5] - The net profit attributable to shareholders was -¥46,504,959.09, representing a decline of 401.69% from ¥15,414,673.27 in the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥46,547,652.26, down 440.51% from ¥13,669,875.91 year-on-year[5] - The basic earnings per share decreased by 401.17% to -¥0.1033 from ¥0.0343 in the same period last year[5] - The diluted earnings per share also fell by 401.17% to -¥0.1033 compared to ¥0.0343 in the previous year[5] - The weighted average return on equity was -3.52%, a decrease of 4.68% from 1.16% in the same period last year[5] - The net profit for the current period is a loss of ¥47,334,078.33, compared to a profit of ¥14,274,902.16 in the previous period, indicating a significant decline in profitability[19] - The company reported a basic and diluted earnings per share of -¥0.1033, down from ¥0.0343 in the previous period[19] - The company’s total comprehensive income for the current period is a loss of ¥47,334,078.33, compared to a profit of ¥14,274,902.16 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,131,222,290.65, down 1.59% from ¥2,165,626,241.76 at the end of the previous year[5] - Shareholders' equity attributable to the parent company was ¥1,304,123,236.35, a decrease of 3.02% from ¥1,344,759,445.44 at the end of the previous year[5] - The company's current assets decreased to CNY 569,053,863.08 from CNY 609,349,135.86, representing a reduction of about 6.6%[14] - Cash and cash equivalents decreased to CNY 114,288,937.74 from CNY 144,398,335.10, indicating a decline of approximately 20.9%[14] - Accounts receivable decreased to CNY 100,693,649.90 from CNY 135,874,624.22, a drop of about 26%[14] - Inventory increased slightly to CNY 240,869,461.17 from CNY 236,429,321.60, showing a growth of approximately 1.84%[14] - Total liabilities increased to CNY 794,663,862.48 from CNY 787,602,485.26, marking an increase of about 0.14%[15] - The company's equity attributable to shareholders decreased to CNY 1,304,123,236.35 from CNY 1,344,759,445.44, a decline of approximately 3%[17] Cash Flow - The company reported a net cash flow from operating activities of -¥31,488,693.26, which is a 20.24% decline compared to -¥26,187,505.67 in the same period last year[5] - Cash flow from operating activities resulted in a net outflow of ¥31,488,693.26, compared to an outflow of ¥26,187,505.67 in the previous period[21] - Cash and cash equivalents at the end of the period decreased to ¥114,288,937.74 from ¥179,523,081.44, reflecting a decline of approximately 36%[23] - The company raised ¥40,000,000.00 through borrowings, a significant increase from ¥2,553,890.33 in the previous period[21] - The total cash outflow from financing activities was ¥16,387,233.35, down from ¥76,638,833.50 in the previous period, indicating a reduction in financing costs[23] Government Support and Community Engagement - The company received government subsidies amounting to ¥105,023.29 during the reporting period, which had a continuous impact on its profits[6] - The company engaged in a public welfare initiative, donating medical masks to schools in minority areas of Hainan, enhancing its community engagement efforts[11] Strategic Initiatives - The company held a strategic conference on March 20, 2024, focusing on the development of the health industry and signed several cooperation agreements, although these will not significantly impact daily operations[11] - Kangzhi Pharmaceutical's chairman participated in the Boao Forum for Asia 2024, discussing the role of overseas Chinese businesses in promoting new productive forces in Hainan's free trade port[11] Operating Costs - Total operating revenue for the current period is ¥104,742,326.30, a decrease of 40% compared to ¥174,602,090.13 in the previous period[18] - Total operating costs decreased to ¥153,590,745.48 from ¥162,087,454.77, with operating costs specifically dropping from ¥85,447,653.94 to ¥49,746,165.33, a reduction of approximately 42%[18] - The company experienced a credit impairment loss of ¥1,177,807.81, contrasting with a gain of ¥5,969,871.12 in the previous period[18]